iktos
Created in 2016
Up & running (A)
Existing signals show a regular activitySocial networks
1,122 115 8,457Activities
Technologies
Entity types
Location
65 Rue de Prony, 75017 Paris, France
Paris
France
Employees
Scale: 51-200
Estimated: 82
SIREN
823189279Engaged corporates
48
10 39Added in Motherbase
6 years, 5 months ago
deeptech Value proposition
Artificial intelligence for new drug design
We are a leader in artificial intelligence and robotic solutions applied to research in medicinal chemistry and new drug design. Iktos' proprietary and innovative generative AI solution enables the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology through the SaaS software platforms MakyaTM for generative drug design and SpayaTM for retrosynthesis, and through strategic collaborations with pharma companies where Iktos mobilizes its unique platform and leading-edge capabilities to expedite small molecule drug discovery for the benefit of its partners. Iktos has also developed Iktos Robotics, a unique AI-driven synthesis automation platform that dramatically accelerates the Design-Make-Test-Analyze cycle in drug discovery and is developing its own pipeline of drug candidates targeting oncology and auto-immune and inflammatory diseases. In March 2023, Iktos completed a 15.5M€ Series A financing round co-led by M Ventures and Debiopharm Innovation with contribution by Omnes Capital. In July 2024, Iktos announced the acquisition of Synsight, thereby complementing its Chemistry AI platform with a groundbreaking biology platform for the discovery of new drugs targeting Protein-Protein Interactions (PPI) and RNA-Protein Interactions (RPI).
artificial intelligence, medicinal chemistry, chemoinformatics, machine learning, deep learning, molecular modeling, CADD, MPO, de novo drug design, drug design, inverse-QSAR, QSAR, lead optimization, Robotics, and AutomationOriginal language
Artificial intelligence for new drug design
We are a leader in artificial intelligence and robotic solutions applied to research in medicinal chemistry and new drug design. Iktos' proprietary and innovative generative AI solution enables the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology through the SaaS software platforms MakyaTM for generative drug design and SpayaTM for retrosynthesis, and through strategic collaborations with pharma companies where Iktos mobilizes its unique platform and leading-edge capabilities to expedite small molecule drug discovery for the benefit of its partners. Iktos has also developed Iktos Robotics, a unique AI-driven synthesis automation platform that dramatically accelerates the Design-Make-Test-Analyze cycle in drug discovery and is developing its own pipeline of drug candidates targeting oncology and auto-immune and inflammatory diseases. In March 2023, Iktos completed a 15.5M€ Series A financing round co-led by M Ventures and Debiopharm Innovation with contribution by Omnes Capital. In July 2024, Iktos announced the acquisition of Synsight, thereby complementing its Chemistry AI platform with a groundbreaking biology platform for the discovery of new drugs targeting Protein-Protein Interactions (PPI) and RNA-Protein Interactions (RPI).
Iktos
https://iktos.ai/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Elaia Startup accelerator & VC, Venture Capital and Private Equity Principals | Elaia Startup accelerator & VC, Venture Capital and Private Equity Principals | Other 19 Nov 2024 | | |
 Ipsen Pharmaceutical, Pharmaceutical Manufacturing | Ipsen Pharmaceutical, Pharmaceutical Manufacturing | Other 7 Nov 2024 | | |
 Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Other 19 Nov 2024 | | |
 France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 26 Nov 2024 | | |
 Teijin Limited Chemistry | Teijin Limited Chemistry | Other 3 Aug 2024 | | |
 Genopole Biotechnology, Biotechnology Research | Genopole Biotechnology, Biotechnology Research | Other 19 Oct 2024 | | |
 La Tribune Media, Newspapers | La Tribune Media, Newspapers | Other 1 May 2024 | | |
 McKinsey & Company Consulting, Business Consulting and Services | McKinsey & Company Consulting, Business Consulting and Services | Other 24 Apr 2024 | | |
 BFM Business Media, Broadcast Media Production and Distribution | BFM Business Media, Broadcast Media Production and Distribution | Other 7 Mar 2025 | | |
 Elsevier Publishing, IT Services and IT Consulting | Elsevier Publishing, IT Services and IT Consulting | Other 29 Jan 2025 | | |